6/26/2025

Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The announcement of a safety update for ELEVIDYS, concerning severe side effects and a temporary shipment suspension for non-ambulatory patients with Duchenne muscular dystrophy, likely exerted significant pressure on the stock, resulting in a 16% decline last week. Additionally, the market's positive momentum, with a 1.7% increase, contrasts sharply with Sarepta’s downturn,...

Source: Yahoo

6/26/2025

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. for violations of §§10 and 20 of the Securities...

Source: Finnhub

6/26/2025

MIAMI, June 26, 2025 -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. securities...

Source: Finnhub

6/25/2025

Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.

Source: Yahoo

6/25/2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock to “Hold” from “Buy,” reducing the price objective to $24 from the prior target of $62, as reported by The Fly. This downgrade reflects the increased probability of withdrawal […]

Source: Yahoo

6/24/2025

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology Designation to the rAAVrh74 viral vector. The vector is utilized in SRP-9003 (bidridistrogene xeboparvovec), which is Sarepta’s investigational gene therapy for the treatment […]

Source: Yahoo

6/24/2025

The U.S. Food and DrugAdministration said on Tuesday that it is investigating reportsof two deaths due to acute liver failure in non-ambulatoryDuchenne muscular dystrophy patients after receiving...

Source: Finnhub

6/24/2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived. Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies. In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent […]

Source: Yahoo

6/20/2025

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.43%. September E-mini S&P futures (ESU25 ) are down -0.21%, and September E-mini Nasdaq futures...

Source: Yahoo

6/20/2025

The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance therapeutics for rare diseases using the gold standard of science.”

Source: Yahoo

6/20/2025

Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.

Source: Yahoo

6/20/2025

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Source: Yahoo

6/20/2025

Discover 12 lesser-covered stocks including Rigetti Computing & Western Union.

Source: SeekingAlpha

6/20/2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Source: Yahoo

6/19/2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Cantor Fitzgerald upgraded Analog Devices (ADI) to Overweight from Neutral with a price target of $270, up from $250. Analog Devices is a “best-in-class” analog company, with “outsized” industrial exposure which is preferential into the upcycle, the firm tells investors in a research note. Argus upgrad

Source: Yahoo

6/19/2025

Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.

Source: Yahoo

6/18/2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Loop Capital upgraded Roku (ROKU) to Buy from Hold with a price target of $100, up from $80. The firm cites expectations that the Amazon.com (AMZN) advertising partnership announced yesterday should begin positively impacting Roku’s financial results starting next year for the upgrade. UBS upgraded Alk

Source: Yahoo

6/17/2025

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc.  . Such investors are advised to contact Danielle Peyton...

Source: Finnhub

6/17/2025

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK. Despite these developments, the company's shares fell 43% last month. This decline may have been influenced by market volatility amid geopolitical tensions and weak economic data. While these broader market factors likely added weight to the movement, Sarepta's price plunge suggests specific...

Source: Yahoo

6/17/2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term compet

Source: Yahoo